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Prevalence of Cerebral Amyloid Pathology
in PersonsWithout Dementia
AMeta-analysis
Willemijn J. Jansen, MSc; Rik Ossenkoppele, PhD; Dirk L. Knol, PhD; Betty M. Tijms, PhD;
Philip Scheltens, MD, PhD; Frans R. J. Verhey, MD, PhD; Pieter Jelle Visser, MD, PhD;
and the Amyloid Biomarker Study Group
IMPORTANCE Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of
amyloid pathology in persons without dementia are needed to understand the development
of AD and to design prevention studies.
OBJECTIVE To use individual participant data meta-analysis to estimate the prevalence of
amyloid pathology as measured with biomarkers in participants with normal cognition,
subjective cognitive impairment (SCI), or mild cognitive impairment (MCI).
DATA SOURCES Relevant biomarker studies identified by searching studies published before
April 2015 using theMEDLINE andWeb of Science databases and through personal
communication with investigators.
STUDY SELECTION Studies were included if they provided individual participant data for
participants without dementia and used an a priori defined cutoff for amyloid positivity.
DATA EXTRACTION AND SYNTHESIS Individual records were provided for 2914 participants
with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies.
MAIN OUTCOMES ANDMEASURES Prevalence of amyloid pathology on positron emission
tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E
[APOE] genotype, sex, and education) estimated by generalized estimating equations.
RESULTS The prevalence of amyloid pathology increased from age 50 to 90 years from 10%
(95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition;
from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from
27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4
carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15%
of the participants with normal cognition were amyloid positive was approximately 40 years
for APOE ε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3
carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly
educated participants but not associated with sex or biomarker modality.
CONCLUSIONS AND RELEVANCE Among persons without dementia, the prevalence of cerebral
amyloid pathology as determined by positron emission tomography or cerebrospinal fluid
findings was associated with age, APOE genotype, and presence of cognitive impairment.
These findings suggest a 20- to 30-year interval between first development of amyloid
positivity and onset of dementia.
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A lzheimerdisease (AD) is themost commoncauseofde-mentia, with a worldwide prevalence of about 25mil-lion in 2010, expected to be doubled by 2030 because
of increased life expectancy.1 The earliest recognizable patho-
logical event inAD is cerebral amyloid-β aggregation.2Thispa-
thology may be present up to 20 years before the onset of
dementia.3,4Novel researchcriteria forAD in individualswith-
out dementia emphasize the presence of amyloid pathology
to define the first stage of the disease.5,6
Prevalence estimates of amyloid pathology in persons
without dementia are needed to better understand the
development of AD and to facilitate the design of AD
prevention studies. Initiation of treatment for AD in the
predementia phase, when neuronal damage is still limited,
may be crucial to have clinical benefit.7 Neuropathological
studies have reported prevalences of amyloid pathology
in nondemented individuals ranging between 10% and
60%.8,9 Studies that assessed amyloid pathology in nonde-
mented individuals during life using biomarkers in cerebro-
spinal fluid (CSF) or on positron emission tomography (PET)
also showed large variability in prevalence estimates
(10%-70%).10-13 This variability may have resulted from
small sample sizes, differences in study design, and partici-
pant selection.
The aim of this study was to estimate the prevalence of
amyloid pathology as assessed by biomarkers in nonde-
mented individuals with an individual participant meta-
analysis. We estimated the prevalence in participants with
normal cognition, subjective cognitive impairment (SCI),
and mild cognitive impairment (MCI) and investigated the
relation with known risk factors for AD-type dementia,
including age, sex, education, and APOE genotype. We also
tested the association of biomarker modality and recruit-
ment strategies with prevalence estimates and compared
age-specific estimates of amyloid positivity in participants
with normal cognition with the prevalence of AD-type
dementia in the general population.
Methods
To identify relevant biomarker studies, the MEDLINE and
Web of Science databases were searched for studies
published before April 2015. The search terms used for PET
studies were PET and (Pittsburgh or PiB or florbetapir or
AV-45 or florbetaben or flutemetamol) and (amyloid or abeta).
The search terms used for CSF studies were (CSF or cerebro-
spinal fluid) and (amyloid or abeta). Titles and abstracts were
reviewed and relevant studies were retrieved. Searches were
restricted to articles published in the English language. Stud-
ies were included if amyloid biomarker data for participants
without dementia were reported and an a priori defined cut-
off for amyloid abnormality was used. Studies that included
participants with neurological, psychiatric, or other diseases
that might affect the central nervous system were excluded.
We also asked partners from 2 European multicenter collab-
orative projects, BIOMARKAPD and EMIF-AD, to provide
unpublished data (Figure 1).
Asmost published studies did not provide prevalence es-
timates according to ageandother risk factors,weasked study
contact persons to provide participant-level data or tabu-
lated data according to 10-year age categories and unpub-
lisheddata if available. Tabulateddatawere converted topar-
ticipant-leveldatawith theaverageage in theagecategory.The
quality of primary articles from each study was systemati-
cally assessed using relevant criteria from the STROBE14 and
QUADAS15 guidelines (eTable 1 in the Supplement). All partici-
pants gave written informed consent to participate. Studies
were approved by the local ethics committees of the partici-
pating centers.
Data Collection andOperationalization
Informationon studyprocedureswas extracted fromthepub-
lication or requested from the study contact person and used
to create a common set of variables.
Cognitive Status,APOE, Sex, and Education
Normal cognition was defined as normal scores on cognitive
tests, the absence of cognitive complaints for which medical
help was sought, or both. Subjective cognitive impairment
was defined as presence of a cognitive complaint with pre-
sentation at a health care facility but normal cognition on
tests. Mild cognitive impairment was defined according to
published criteria.16,17 These include a decline in memory or
another cognitive domain reported by the patient, infor-
mant, or both and objectively verified by neuropsychologi-
cal testing, in combination with no or minimal impairment
in activities of daily living and not meeting criteria for
dementia. Mild cognitive impairment was subclassified as
amnestic MCI or nonamnestic MCI when possible. Informa-
tion on APOE-ε4 carrier status (yes/no), APOE genotype,
and years of education was retrieved. To describe the asso-
ciation of APOE genotype with age, we reported for each
genotype the age at which 15% of the participants with nor-
mal cognition were amyloid positive as a proxy for first
appearance of abnormal amyloid.
Setting and Recruitment
The study setting was classified as clinical if patients pre-
sented with cognitive complaints at a health care facility; re-
search if patients were asked to participate in research by re-
cruitment through advertisements or from other hospital
departments; population-based if a randomsampleof thegen-
eral populationwas included; ormixed if participantswere re-
cruited from a combination of settings.
Amyloid Assessment
Measurementdetailsdocumented includedamyloid tracerand
assessment via visual scales or quantitativemeasures for PET
studies andassayused tomeasure amyloid-β1-42 levels forCSF
studies. Positron emission tomography and CSF biomarkers
were dichotomized as negative (normal) or positive (abnor-
mal) according to study-specific cutoffs. (See eTables 2 and 3
in the Supplement formeasurement details.) For participants
whohadbothPETandCSFamyloidmeasures,we selected the
first amyloid measure in time.
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ComparisonWith Prevalence of AD-Type Dementia
Age- and APOE-specific prevalence data of AD-type demen-
tia were obtained through ameta-analysis or from published
lifetime risk data for AD-type dementia18 as described in the
eMethods in the Supplement.
Number Needed to Screen
Touse theprevalenceestimates in selectingparticipants at risk
for amyloid positivity for AD prevention studies, numbers
neededtoscreento identify1amyloid-positiveparticipantwere
calculated as described in the footnote of eTable 6 in the
Supplement.
Statistical Analysis
We conducted a meta-analysis with individual participant
data, in which original research data were sought directly
from study contact persons, combined, and reanalyzed cen-
trally. Generalized estimating equations (GEEs) were used to
estimate the prevalence and odds ratios (ORs). Generalized
estimating equations allow for analysis of binary correlated
data such that participant-level data on the prevalence from
all studies could be modeled while simultaneously account-
ing for the clustering of participants within studies. We
assumed a logit link function for binary outcome with an
exchangeable correlation structure to account for within-
study correlation. Analyses were performed using SPSS ver-
sion 20.0 (IBM) with the genlin command. They were con-
ducted using the total study population unless specified
otherwise.
The main analyses were performed with cognitive sta-
tus (normal cognition, SCI, MCI), age, sex, education, and
APOE-ε4 genotype as independent variables. Age was
entered as a continuous measure centered at the median.
Educational level was dichotomized at the median (high,
≥14 years, vs moderate to low, <14 years). Secondary analy-
ses tested associations with biomarker modality, MCI sub-
type, published vs unpublished studies, setting, and recruit-
ment strategy while adjusting for cognitive status, age, and
APOE-ε4 carrier status. We tested 2-way and 3-way interac-
tions between variables and age as a quadratic term, and
Figure 1. FlowDiagram of Literature Search and Study Selection
7578 Records identified through
database search
6979 Excluded based on review of title
and abstract
3701 Other topic, method, or design
601 Review, opinion, case study, book,
or abstract only
1760 Duplicates
618 Included patients with dementia
or other diseases
299 Animal study
36 Study contacts did not provide
individual data or did not respond
31 Published studies
5 Unpublished studies
555 Studies excluded after full review
533 Duplicates
3 No biomarker cutoff available
7 Included patients with neurological
or psychiatric diseases
6 Biomarker cutoff determined using
population under study
3 Full text not available
1 No clear diagnosis
1 Pilot study
1 Amyloid not measured in patients
without dementia
599 Full-text articles assessed
for eligibility
47 Studies identified from 2 European
multicenter collaborative projects a
91 Unique studies identified
80 Published studies
11 Unpublished studies
55 Studies included in individual
participant meta-analysis
(n = 8694 participants)
a The EuropeanMedical Information
Framework–Alzheimer Disease
(EMIF-AD) and Biomarkers for
Alzheimer Disease and Parkinson
Disease (BIOMARKAPD) projects.
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these were retained in the equation in case of a significant
Wald statistic as indicated in table footers and figure leg-
ends. Analyses were repeated using natural cubic splines
with knots at ages 50, 60, 70, and 80 years, but this did not
improve the model. Estimated probabilities and 95% confi-
dence intervals from the GEE analyses were used in tables.
Probabilities estimated by GEE were compared with the
observed probabilities in 5-year age groups.
The extent of between-study variability was investi-
gated in several ways. In the total sample, the random inter-
cept variance related to study was estimated in a random-
effects analysis with the independent variables age,
APOE-ε4 carrier status, cognitive status, and interactions
using the xtmelogit function from Stata version 12.0 (Stata-
Corp). This variance was expressed as an intraclass correla-
tion coefficient. In diagnostic and APOE subgroups, hetero-
geneity within 5-year age strata was assessed with the I2
statistic19 from a random-effects meta-analysis in Stata ver-
sion 12.0. An I2 statistic value greater than 50% was consid-
ered indicative for substantial heterogeneity.19 Center vari-
ability across the age range was visualized by plotting the
prevalence for studies with more than 50 participants.
Significance level was set at P < .05 in 2-sided tests, un-
corrected for multiple comparisons. When associations
changed after correcting for multiple comparisons with the
Bonferroni method, this was mentioned in the text or table.
R version 3.1.2 (R Foundation for Statistical Computing) and
GraphPad Prism version 6.0 (GraphPad Software) were used
forgraphswithestimatedprobabilities and95%confidence in-
tervals from the GEE analyses.
Results
The literature search resulted in 7578 publications; amyloid
was assessed by PET in 890 and by CSF in 6688. From these,
599 were selected for full-text review. We identified 47 stud-
ies from the European multicenter projects (Figure 1). A
total of 91 unique studies met inclusion criteria; the authors
of 55 studies agreed to share data. Contact persons from 54
studies provided participant-level data and 1 provided tabu-
lated data (n = 137). Of the 36 studies for which contact per-
sons refused or did not reply, 31 were selected through the
literature search and 5 from the European multicenter stud-
ies. Characteristics of the 31 excluded published studies did
not differ from those of the 55 included studies (eTable 4 in
the Supplement).
Study Characteristics
Of the selected studies, 45 were single-center and 10 were
multicenter studies. (eTable 5 in the Supplement shows
detailed study information.) Forty-one studies provided data
for participants with normal cognition, 20 for patients with
SCI, and 47 for patients with MCI. Of the MCI studies, 8 clas-
sified patients with MCI as amnestic MCI or nonamnestic
MCI, 10 studies only included patients with amnestic MCI,
and all other studies used a broad MCI definition or did not
specify MCI subtype. Information on APOE-ε4 carrier status
was provided by 41 studies and information on APOE geno-
type by 37 studies. All studies but 1 specified the sex of the
participants. Information on years of education was avail-
able from 44 studies. Studies contributing data for partici-
pants with normal cognition were performed in a research
setting in 95% (n = 39, selection through advertisements in
15, from hospitals in 10, and from other or unknown sources
in 14) and a mixed setting in 5% (n = 2). Forty-six of the stud-
ies (98%) that included patients with SCI or MCI were per-
formed in a clinical setting.
Amyloid-PET data were provided by 29 studies. Of these,
22 studies used [11C]Pittsburgh compound-B (PiB),
9 [18F]florbetapir, 2 [18F]florbetaben, and 1 [18F]flutemetamol,
including 5 that used multiple tracers. Eleven studies
assessed the PET images by visual scales whereas 16 studies
used quantitative assessment and 2 studies used both meth-
ods. Cerebrospinal fluid amyloid-β1-42 data were provided
by 31 studies. The Innotest enzyme-linked immunosorbent
assay (Fujirebio Europe) was used for CSF analysis in 29
studies and the xMAP Luminex assay in 2 studies. Two stud-
ies (1111 participants) provided data on both PET and CSF
amyloid measures. Primary studies were assessed with the
quality rating criteria, and typically met all criteria,
although bias could not be assessed in 37 publications and
participant flow remained unclear in 2 publications (eTable
1 in the Supplement).
Participant Characteristics
We included 7583 participants from 55 studies, of whom
2914 (38%) had normal cognition, 697 (9%) SCI, and 3972
(52%) MCI. Amyloid positivity was assessed with PET for
2370 participants (31%; 1346 normal cognition, 35 SCI, 989
MCI) and with CSF for 5213 participants (69%; 1568 normal
cognition, 662 SCI, 2983 MCI). Baseline characteristics
according to cognitive status are shown in Table 1. Partici-
pants with missing APOE data did not differ in amyloid
positivity and sex from participants with APOE data but
more often had limited education (63%) compared with par-
ticipants who had these data available (48%, χ = 62.5,
P < .001). Participants with missing sex or education data
did not differ in amyloid positivity, sex or education, and
APOE-ε4 carrier status from participants with these data.
Prevalence of Amyloid Positivity
Estimated probabilities of amyloid positivity according to
cognitive status, APOE-ε4 status, and age are displayed in
Figure 2, Figure 3A and B, and Table 2. Observed prevalence
estimates are shown in Table 3. The difference between the
observed and predicted prevalence rates was less than 10%
in more than 90% of the comparisons indicating good
model fit. Amyloid positivity was about twice as common in
patients with MCI compared with participants with normal
cognition (mean difference, 25% [95% CI, 22% to 28%];
P < .001) or SCI (mean difference, 23% [95% CI, 14% to 32%];
P < .001), while it did not differ between participants with
normal cognition and SCI (mean difference, 2% [95% CI,
−6% to 10%]; P = .62). Amyloid positivity increased with age
in all diagnostic groups.
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APOE-ε4 carriers had 10% to 40% higher absolute
prevalence estimates than noncarriers in each diagnostic
group (Table 2, Figure 3A and B). At the median age of 70
years, the prevalence estimates were different between all
APOE genotypes in participants with normal cognition,
except for those of the ε2ε4 and ε3ε4 genotypes, which did
not differ from each other (mean difference ε4ε4 vs ε3ε4,
38% [95% CI, 22% to 53%]; P < .001, vs ε2ε4, 28% [95% CI,
7% to 49%]; P = .008, vs ε3ε3, 60% [95% CI, 44% to 75%];
P < .001, vs ε2ε3, 73% [95% CI, 58% to 87%]; P < .001; mean
difference ε3ε4 vs ε2ε4, 9% [95% CI, −1% to 20%]; P = .08,
vs ε3ε3, 22% [95% CI, 18% to 26%]; P < .001, vs ε2ε3, 35%
[95% CI, 29% to 40%]; P < .001; mean difference ε2ε4 vs
ε3ε3, 31% [95% CI, 21% to 42%]; P < .001, vs ε2ε3, 44% [95%
CI, 31% to 57%]; P < .001; mean difference ε3ε3 vs ε2ε3, 13%
[95% CI, 8% to 17%]; P < .001) (Figure 3C).
After correction for multiple comparisons, ε2ε4 and
ε4ε4 showed no statistically significant difference (P = .08).
None of the 10 participants with ε2ε2 were amyloid positive.
APOE genotype was associated with the age at onset of amy-
loid positivity. For example, the age at which 15% of the par-
ticipants with normal cognition were amyloid positive was
approximately 40 years for ε4ε4 carriers, 50 years for ε2ε4
carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers,
Table 1. Baseline Study Participant Characteristics
Characteristic
Normal Cognition
(n = 2914)
SCI
(n = 697)
MCI
(n = 3972)
Age (n = 2914) (n = 697) (n = 3971)
Mean (SD), y 66.8 (13.2) 64.2 (8.0) 70.2 (8.7)
Age groups, No. (%), y
<40 140 (4.8) 1 (0.1) 1 (0.0)
40-44 28 (1.0) 3 (0.4) 10 (0.3)
45-49 80 (2.7) 12 (1.7) 31 (0.8)
50-54 178 (6.1) 48 (6.9) 113 (2.8)
55-59 258 (8.9) 158 (22.7) 349 (8.8)
60-64 361 (12.4) 170 (24.4) 541 (13.6)
65-69 530 (18.2) 126 (18.1) 763 (19.2)
70-74 567 (19.5) 103 (14.8) 883 (22.2)
75-79 380 (13.0) 56 (8.0) 745 (18.8)
80-84 263 (9.0) 16 (2.3) 385 (9.7)
85-89 102 (3.5) 4 (0.6) 131 (3.3)
≥90 27 (0.9) 0 19 (0.5)
Sex, No. (%) (n = 2796) (n = 697) (n = 3972)
Female 1537 (55.0) 348 (49.9) 1839 (46.3)
Male 1259 (45.0) 349 (50.1) 2133 (53.7)
Education (n = 2280) (n = 364) (n = 2926)
Mean (SD), y 14.6 (3.6) 12.1 (4.3) 12.5 (4.4)
Education by category, No. (%) (n = 2280) (n = 539) (n = 3099)
<14 y 815 (35.7) 356 (66.0) 1854 (59.8)
≥14 y 1465 (64.3) 183 (34.0) 1245 (40.2)
MMSE scorea (n = 2592) (n = 693) (n = 3910)
Mean (SD) 29.0 (1.3) 28.4 (1.5) 26.8 (2.5)
Assessment by PET biomarker 1346 (46.2) 35 (5.0) 989 (24.8)
Assessment by CSF biomarker 1568 (53.8) 662 (95.0) 2983 (75.2)
Biomarker abnormal, No. (%)
Amyloid PET 328 (24.4) 8 (22.8) 523 (52.9)
CSF β amyloid 415 (26.5) 144 (21.8) 1513 (50.7)
APOE-ε4 carrier status, No. (%) (n = 2289) (n = 533) (n = 3118)
APOE-ε4 negative 1614 (70.5) 322 (60.4) 1650 (52.9)
APOE-ε4 positive 675 (29.5) 211 (39.6) 1468 (47.1)
APOE genotype, No. (%) (n = 2130) (n = 533) (n = 2837)
ε2ε2 10 (0.5) 1 (0.2) 5 (0.2)
ε2ε3 255 (12.0) 49 (9.2) 211 (7.4)
ε2ε4 41 (1.9) 13 (2.4) 62 (2.2)
ε3ε3 1228 (57.7) 272 (51.0) 1267 (44.7)
ε3ε4 531 (24.9) 178 (33.4) 991 (34.9)
ε4ε4 65 (3.1) 20 (3.8) 301 (10.6)
Abbreviations: APOE, apolipoprotein
E; CSF, cerebrospinal fluid;
MCI, mild cognitive impairment;
MMSE, Mini Mental State
Examination; PET, positron emission
tomography; SCI, subjective cognitive
impairment.
a Range 0-30, with 30 as the best
score.
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and 95 years for ε2ε3 carriers. In patients with SCI, preva-
lence of amyloid pathology according to APOE genotype
was similar to participants with normal cognition in all age
groups (mean difference, 1% [95% CI, −11% to 12%]; P = .92).
In patients with MCI, the prevalence differed between geno-
types at the median age of 70 years, while again the ε2ε4
and ε3ε4 genotypes did not differ from each other; the dif-
ference between the ε2ε4 and ε3ε3 genotypes was not sta-
tistically significant (mean difference ε4ε4 vs ε3ε4, 23%
[95% CI, 17% to 29%]; P < .001, vs ε2ε4, 33% [95% CI, 14% to
51%]; P = .001, vs ε3ε3, 54% [95% CI, 47% to 60%]; P < .001,
vs ε2ε3, 64% [95% CI, 57% to 71%]; P < .001; mean differ-
ence ε3ε4 vs ε2ε4, 10% [95% CI, −9% to 28%]; P = .31, vs
ε3ε3, 31% [95% CI, 25% to 37%]; P < .001, vs ε2ε3, 41% [95%
CI, 34% to 48%]; P < .001; mean difference ε2ε4 vs ε3ε3, 21%
[95% CI, −1% to 43%]; P = .06, vs ε2ε3, 31% [95% CI, 9% to
53%]; P = .005; mean difference ε3ε3 vs ε2ε3, 10% [95% CI,
6% to 14%]; P < .001) (Figure 3D).
Patients with MCI and the APOE ε2ε2 genotype were not
included in the analysis because of the small sample size
(n = 5, of whom 1 was amyloid positive). The prevalence of
amyloid pathology in patients with MCI at age 70 years was
89% (95% CI, 81%-94%) for ε4ε4 carriers, 66% (95% CI,
60%-72%) for ε3ε4 carriers, 57% (95% CI, 35%-76%) for ε2ε4
carriers, 35% (95% CI, 31%-40%) for ε3ε3 carriers, and 25%
(95% CI, 19%-32%) for ε2ε3 carriers. Table 4 shows the ORs
for amyloid positivity of the APOE genotypes relative to the
ε3ε3 genotype at age 70 years for participants with normal
cognition and MCI.
The prevalence of amyloid pathology at the mean age
was 5% higher (95% CI, 1% to 8%; P = .005) in participants
with an education above the median (n = 2530) than in
those with education below the median (n = 2415) regard-
less of cognitive status, age, and APOE-ε4 carrier status
(eFigure 1 in the Supplement). There was no significant
association with or interaction between sex and any of the
risk factors for amyloid positivity (mean difference, 1% [95%
CI, −1% to 3%]; P = .52).
ComparisonWith Prevalence of AD-Type Dementia
The age-related increase in amyloid positivity in participants
withnormal cognitionparalleledage-specificAD-typedemen-
tia prevalence estimates, with an intervening period of about
20 years (Figure 4A). Similarly, APOE genotype–specific esti-
mates of amyloid positivity paralleled APOE genotype–
specific lifetime risks of AD-type dementia with a difference
of 25 to 30 years (Figure 4B).
Number Needed to Screen
The numbers of participants needed to screen (NNS) to
identify 1 amyloid-positive person are displayed according
to age, cognitive status, and APOE genotype in eTable 6 in
the Supplement. The NNS varied from 1.0 (95% CI, 1.0-1.1),
for persons with normal cognition or MCI who were older
than 70 years with the APOE ε4ε4 genotype, to 16.7 (95% CI,
11.1-25.0), for persons with normal cognition aged 50 years
without an APOE-ε4 allele. If APOE genotype is unknown,
participants need to be screened for this first. The number
of participants for whom APOE genotyping needs to be per-
formed to find 1 participant with that particular APOE geno-
type who is amyloid positive varied between 3.5 (95% CI,
2.8-4.3), for persons with normal cognition aged 90 years
without an APOE-ε4 allele, to 89.6 (95% CI, 64.5-129.0), for
persons with normal cognition aged 50 years with the APOE
ε4ε4 genotype.
Assessment of Study-Related Heterogeneity
In the total study population, the intraclass correlation coef-
ficient for study-related random intercept variancewas0.085,
indicating minor heterogeneity among studies. Within age,
APOE-ε4, and diagnostic subgroups, heterogeneity was not
substantial according to the I2 statistic, except for 2 of 54 sub-
groups (50%-60%inagegroup65-69yearsof SCIAPOE-ε4 car-
riers and in age group 75-79 years of MCI APOE-ε4 noncarri-
ers) (eTable 7 in the Supplement).
Visual inspection of variability in prevalence estimates
across age in studies with at least 50 participants also indi-
cated that between-study variability was small (eFigure 2 in
the Supplement).
Post Hoc Analyses
The biomarker used to assess amyloid positivity was not
associated with prevalence (mean difference, 0% [95% CI,
−7% to 8%]; P = .87) for participants with normal cognition
or MCI (n = 6885). Patients with SCI were excluded because
amyloid was measured with PET in only 5% of participants.
While adjusting for APOE-ε4 carrier status and age, amyloid
prevalence at the mean age was higher in patients with
amnestic MCI (n = 1405) than in patients with nonamnestic
MCI (n = 225, 58% [95% CI, 48% to 67%] vs 47% [95% CI,
35% to 60%], mean difference, 11% [95% CI, 0% to 21%];
P = .03) and higher in patients with nonamnestic MCI than
in participants with normal cognition (n = 2289, mean dif-
ference, 15% [95% CI, 2% to 28%]; P = .03). The prevalence
Figure 2. Association of AgeWith Prevalence Estimates of Amyloid
Positivity According to Cognitive Status
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equations. Themodel included age and cognitive status as predictors. Shading
indicates 95% CIs; SCI, subjective cognitive impairment; MCI, mild cognitive
impairment.
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did not differ between amnestic MCI (n = 1405) and MCI
patients diagnosed using a broad or unspecified definition
of MCI (n = 1487, mean difference, 3% [95% CI, −6% to 13%];
P = .51). Prevalence estimates did not differ for published
and unpublished studies (eTable 8 in the Supplement). The
prevalence in participants with normal cognition recruited
via advertisements (n = 1868) was similar to that of partici-
pants recruited from hospital departments (n = 305, mean
difference, 4% [95% CI, −13% to 21%]; P = .96).
Discussion
This amyloid biomarker study including individuals with-
out dementia provides prevalence estimates of amyloid
pathology over an age range of 18 to 100 years for persons
with normal cognition, SCI, and MCI. The age at onset of
amyloid positivity was associated with cognitive status and
the APOE genotype. At age 90 years, about 40% of the
APOE-ε4 noncarriers and more than 80% of APOE-ε4 carri-
ers with normal cognition were amyloid positive. Amyloid
positivity was associated with education but not with sex or
biomarker modality. The age-related prevalence of amyloid
positivity in participants with normal cognition paralleled
the age-related prevalence of AD-type dementia in the gen-
eral population in an APOE genotype–specific way with a
time lag of 20 to 30 years.
Patients with MCI had 20% to 30% higher prevalence es-
timates of amyloid positivity than those with normal cogni-
tionorSCI, supporting theviewthatMCI is a risk state forAD.16
Cognitively normal and SCI groups did not differ in amyloid
positivity, suggesting that the presence of SCI in a memory
clinicpopulationmightnotbeassociatedwithan increasedrisk
for AD. Previous studies in other settings showed inconsis-
tent results regarding differences in amyloid positivity be-
tween cognitively normal and SCI participants,20,21 indicat-
Figure 3. Association of AgeWith Prevalence Estimates of Amyloid Positivity According to Cognitive Status and Apolipoprotein E (APOE)Genotype
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Themodel for the analyses in panels A and B included age, cognitive status,
APOE-ε4 status, an interaction between age and cognitive status, and an
interaction between age and APOE-ε4 status as predictors. Themodels for the
analyses in panels C and D included age, cognitive status, APOE genotype, an
interaction between age and cognitive status, an interaction between age and
APOE genotype, and an interaction between cognitive status and APOE
genotype as predictors. In panel C, none of the 10 participants with ε2ε2 were
amyloid positive, and no 95% confidence interval is provided for this group. In
panel D, data of participants with ε2ε2 are not shown because of the small
sample size (n = 5). Shading indicates 95% CIs; SCI, subjective cognitive
impairment; MCI, mild cognitive impairment.
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ing that further research is needed on this. Patients with
nonamnesticMCI had lower prevalence estimates of amyloid
positivity thanpatientswithamnesticMCIbuthigher thanpar-
ticipants with normal cognition. This suggests that both am-
nestic MCI and nonamnestic MCI are associated with an in-
creased risk forADand that this risk is higher for patientswith
amnestic MCI. The observation that a substantial number of
patientswithMCIwerenot amyloidpositive, evenatolder age,
suggests that theMCI phenotype does not always have AD as
underlying pathology. Possible non-AD causes inMCImay be
hippocampal sclerosis, mild depression, or vascular damage.
Age was a risk factor for amyloid positivity, which is in
line with the finding that age is an important risk factor for
postmortem amyloid load22 and for AD-type dementia,23 as
also shown in Figure 4A. The prevalence of amyloid positiv-
ity in participants with normal cognition aged 50 to 60 years
was somewhat higher than found in an earlier population-
based study that was not included in our analysis.24 This
could relate to differences in recruitment strategy and
assessment.
Relative to theAPOE-ε3 allele, theAPOE-ε4 risk allelewas
associated with a greater risk for amyloid positivity and de-
Table 3. Observed Probabilities of Amyloid Positivitya
Age Group
Normal Cognition SCI MCI
Total APOE-ε4− APOE-ε4+ Total APOE-ε4− APOE-ε4+ Total APOE-ε4− APOE-ε4+
47.5-52.4 y 13.2
(15/114)
7.9
(5/63)
17.2
(5/29)
19.2
(5/26)
0.0
(0/8)
0.0
(0/8)
25.0
(16/64)
19.4
(7/36)
44.4
(8/18)
52.5-57.4 y 15.3
(38/249)
6.9
(8/116)
23.1
(15/65)
10.6
(12/113)
8.3
(4/48)
7.3
(3/41)
26.6
(78/293)
22.0
(24/109)
53.8
(42/78)
57.5-62.4 y 12.1
(36/296)
10.0
(16/160)
26.1
(12/46)
16.9
(29/171)
5.2
(5/96)
35.2
(19/54)
39.1
(181/463)
30.4
(58/191)
51.4
(95/185)
62.5-67.4 y 22.6
(110/485)
13.4
(31/232)
40.6
(54/133)
16.8
(24/143)
4.5
(3/66)
30.4
(14/46)
45.5
(303/666)
27.7
(74/267)
67.1
(171/255)
67.5-72.4 y 24.1
(128/530)
17.1
(50/292)
40.7
(55/135)
26.0
(32/123)
16.1
(9/56)
42.9
(12/28)
54.5
(461/845)
35.0
(104/297)
77.1
(272/353)
72.5-77.4 y 32.2
(164/510)
23.3
(70/301)
61.3
(65/106)
44.0
(33/75)
25.0
(7/28)
59.3
(16/27)
57.2
(494/864)
44.4
(154/347)
79.1
(250/316)
77.5-82.4 y 42.0
(111/264)
35.1
(60/171)
65.5
(36/55)
31.8
(7/22)
33.3
(3/9)
62.1
(323/520)
49.2
(117/238)
86.9
(153/176)
82.5-87.4 y 49.0
(103/210)
41.7
(55/132)
76.5
(39/51)
57.1
(8/14)
50.0
(4/8)
60.3
(135/224)
51.4
(57/111)
81.9
(59/72)
87.5-92.4 y 51.0
(25/49)
42.9
(15/35)
87.5
(7/8)
61.4
(35/57)
58.5
(24/41)
100.0
(7/7)
Abbreviations: APOE, apolipoprotein E; MCI, mild cognitive impairment;
SCI, subjective cognitive impairment.
a Data are observed probabilities in% (No. amyloid positive/No. total
subgroup). No estimates were provided if the age group included
<5 participants.
Table 2. Prevalence Estimates of Amyloid Positivity According to Age, Cognitive Status, andAPOE-ε4 Carrier Statusa
Normal Cognition, % (95% CI) SCI, % (95% CI) MCI, % (95% CI)
Age, y Total APOE-ε4− APOE-ε4+ Total APOE-ε4− APOE-ε4+ Total APOE-ε4− APOE-ε4+
50 10.4
(8.1-13.3)
5.7
(3.6-8.9)
14.9
(10.2-21.2)
11.6
(7.3-17.8)
3.9
(1.9-7.8)
10.6
(6.2-17.5)
26.9
(22.5-31.7)
18.7
(14.2-24.2)
40.0
(33.2-47.2)
55 12.9
(10.3-16.0)
7.6
(5.2-11.0)
20.9
(15.5-27.5)
14.2
(9.3-21.2)
5.6
(3.1-10.0)
16.1
(10.4-24.0)
31.8
(27.5-36.4)
22.2
(17.8-27.3)
47.9
(41.7-54.2)
60 15.8
(12.9-19.1)
10.0
(7.4-13.5)
28.6
(22.9-35.1)
17.4
(11.6-25.2)
8.0
(4.9-12.7)
23.7
(16.9-32.2)
37.1
(32.9-41.6)
26.1
(21.9-30.7)
55.9
(50.5-61.2)
65 19.2
(16.0-22.9)
13.2
(10.4-16.6)
37.8
(32.0-43.9)
21.1
(14.4-29.7)
11.2
(7.6-16.3)
33.5
(25.9-42.5)
42.8
(38.7-47.1)
30.4
(26.5-34.6)
63.6
(59.0-68.0)
70 23.1
(19.5-27.2)
17.1
(14.1-20.6)
47.9
(42.2-53.7)
25.3
(17.7-34.8)
15.5
(11.3-20.9)
45.0
(36.9-53.4)
48.7
(44.5-53.0)
35.1
(31.3-39.2)
70.7
(66.6-74.4)
75 27.6
(23.4-32.3)
21.9
(18.4-25.9)
58.2
(52.3-63.8)
30.0
(21.4-40.3)
21.2
(16.1-27.3)
57.1
(48.7-65.1)
54.6
(50.2-59.0)
40.1
(35.9-44.6)
76.9
(73.1-80.2)
80 32.6
(27.6-38.0)
27.7
(23.0-32.9)
67.8
(61.6-73.5)
35.2
(25.6-46.2)
28.1
(21.5-35.8)
71.5
(63.0-78.8)b
60.4
(55.7-65.0)
45.4
(40.2-50.7)
82.1
(78.5-85.2)
85 38.0
(32.2-44.2)
34.2
(27.7-41.4)
76.2
(69.8-81.6)
40.8
(30.3-52.3)
36.3
(27.3-46.4)
74.0
(65.5-81.0)b
66.0
(60.8-70.7)
50.7
(44.3-57.1)
86.3
(82.9-89.2)
90 43.8
(37.0-50.7)
41.5
(32.7-50.8)
82.9
(76.6-87.7)
43.1
(32.2-54.7)b
39.9
(29.7-51.0)b
71.1
(65.7-75.9)
56.1
(48.3-63.5)
89.1
(85.9-91.7)b
Abbreviations: APOE, apolipoprotein E; MCI, mild cognitive impairment;
SCI, subjective cognitive impairment.
a The prevalence estimates were generated from generalized estimating
equations. Amyloid positivity in the total group wasmodeled using age and
cognitive status as predictors. Amyloid positivity according to APOE-ε4 status
was modeled with age, cognitive status, APOE-ε4 status, an interaction
between age and cognitive status, and an interaction between age and
APOE-ε4 status. Table 3 displays the number of participants and observed
probabilities of amyloid positivity per age subgroup. No estimate was provided
if the 5-year range around the indicated column age included no participants.
bNo participants available with the exact age; prevalence estimated at
nearest age.
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creased age at onset, while the APOE-ε2 allele had the oppo-
site associations. This is similar to the relation ofAPOE geno-
type with the risk for AD-type dementia and age at onset of
AD-type dementia as reported in clinical studies25,26 and the
APOE genotype–specific lifetime risk for AD as shown in
Figure 4B. The high prevalence of amyloid positivity in par-
ticipantswithnormal cognition andMCIwith ε2ε4 in thepre-
sent study indicates that the detrimental relation of amyloid
positivity with ε4 outweighs the protective association with
ε2, in line with clinical AD studies.27 The OR for amyloid pa-
thology of the APOE genotypes relative to the ε3ε3 genotype
was similar to the OR for AD-type dementia in case-control
studies.18,27 The strongassociationof theAPOEgenotypewith
amyloidpositivityemphasizesAPOEasan important target for
treatment studies.28,29
Highly educated participants had a higher prevalence of
amyloidpathology than thosewith less formal education.This
mayseemincontrastwith the finding thathigheducation level
is associated with a lower risk for AD-type dementia30 but is
in agreementwith the cognitive reservehypothesis.31 Accord-
ing to this hypothesis, nondemented individuals with a high
level of education have a greater cognitive reserve such that
they can sustain more amyloid pathology before developing
dementia. Education itself was not associated with the ex-
Figure 4. Comparison of the Prevalence of Amyloid PositivityWith the Prevalence of and Lifetime Risks for Alzheimer Disease–Type Dementia
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The prevalence estimates in panel A were estimated from ameta-analysis of 14
studies (eMethods in the Supplement). The prevalence estimates in panel B of
amyloid positivity in participants with normal cognition are plotted against
published lifetime risks for Alzheimer disease (AD)–type dementia by APOE
genotype (adapted from Genin et al18).
Table 4. Odds Ratios for the Association BetweenAPOEGenotype and Amyloid Positivity at Age 70 Yearsa
APOE Genotype
ε3ε3 ε2ε3 ε2ε4 ε3ε4 ε4ε4
Normal cognition
OR (95% CI) 1 [Reference] 0.34 (0.23-0.51) 4.29 (2.67-6.90) 2.94 (2.34-3.70) 18.76 (5.47-64.37)
P value <.001 <.001 <.001 <.001
No. amyloid positive (%) 275 (22.4) 22 (8.6) 17 (41.5) 213 (40.1) 45 (69.2)
MCI
OR (95% CI) 1 [Reference] 0.59 (0.48-0.73) 2.38 (0.98-5.81) 3.52 (2.73-4.55) 14.50 (8.14-25.81)
P value <.001 .06 <.001 <.001
No. amyloid positive (%) 490 (38.7) 57 (27.0) 35 (56.5) 666 (67.2) 261 (86.7)
Abbreviations: APOE, apolipoprotein E; OR, odds ratio; MCI, mild cognitive
impairment.
a The ORs were generated from generalized estimating equations separately in
participants with normal cognition andMCI. Themodels included age, APOE
genotype, an interaction between age and APOE genotype, and a quadratic
age term in the normal cognitionmodel as predictors. P values represent the
significance of the OR for amyloid positivity compared with the ε3ε3
genotype. The ε2ε2 genotype was excluded because of the small number of
participants in this group.
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tent of pathology at postmortem examination32 but might
modify the relationship between AD pathology and expres-
sionofdementia,33 resulting inhigheramyloidpositivitypreva-
lence innondementedhighly educatedparticipants. Analter-
nativeexplanationwouldbe thathighlyeducatedpersonswith
amyloid pathology may be overrepresented in study partici-
pation or clinical care seeking due to self-selection bias.
Our finding that the prevalence of amyloid positivitywas
the same for men and women is in line with a previous neu-
ropathological studyshowingnodifference inneuritic anddif-
fuse plaque load between men and women.34 This finding is
also in agreement with another earlier study,35 as is our find-
ing that therewasno interactionbetweensexandAPOE-ε4car-
rier status on amyloid positivity.
Although PET and CSF are thought to measure different
types of amyloid-β,36 we did not find differences in amyloid
positivity estimates for PETandCSFbiomarkers. This is in line
with published high concordance rates of 84% to 92% be-
tweenthe2biomarkers.37,38Also,high levelsofagreementhave
been reported for studies that providedmore than 50 partici-
pants to our study in whom amyloid was assessed with both
PET and CSF.39,40
We pooled data from a large number of studies, and this
mayhave introducedbias because of differences in themeth-
odsunderlying amyloid assessment, cutoff definition, partici-
pant selection, diagnostic criteria, and other aspects of study
design.However, in the total study sample; in age,APOE, and
diagnostic subgroups; and on visual inspection of study-
specific prevalences over age, there was limited evidence for
study-relatedheterogeneity,whichsupports thepoolingofdata
from different studies (eFigure 2 and eTable 7 in the Supple-
ment). Moreover, the Alzheimer’s Association Quality Con-
trol program for CSFbiomarkers reported that overall concor-
dance for diagnostic classification was high between centers
despite analytical variance.41 We also explored the associa-
tion of a number of study characteristics with the prevalence
in post hoc analyses, but no relation was found. An advan-
tageofparticipant-levelanalysisoveraggregatedpooling is that
the power to detect subgroup effects is increased,42while the
risk for ecological bias is decreased.43
A limitationof this study is that our participantswithnor-
mal cognitionweremostly recruitedvia advertisements,mak-
ing this samplevulnerable to self-selectionbias44 and restrict-
inggeneralizability to thegeneralpopulation.Participantswith
SCI andMCIweremostly recruited fromclinical settings, ren-
dering them dissimilar from these individuals in the general
population. Participants with significant comorbid disorders
areusuallyexcludedfromparticipation,andstudiesoftenused
standardized cognitive screens, which also affects generaliz-
ability. Although MCI was not classified as amnestic or non-
amnestic for most participants, our findings indicate that we
mostly included amnestic MCI patients because the preva-
lence estimates in amnestic MCI patients did not differ from
those with a broad or unspecified definition of MCI. Still, pa-
tientswith nonamnesticMCI had a lower prevalence thanpa-
tientswith amnesticMCI, suggesting that this is an important
distinction to make in future research. Moreover, our preva-
lence estimates are based on cross-sectional data. The life-
time risk for individuals without dementia to develop amy-
loidpathologywill behigher than the cross-sectional estimate
at any age because amyloid-positive personsmaydie or prog-
ress to dementia at follow-up.
This studyhas several implications for understanding the
development of AD. The observation that key risk factors for
AD-type dementia are also risk factors for amyloid positivity
in cognitively normal persons provides further evidence for
thehypothesis that amyloidpositivity in these individuals re-
flects earlyAD.Further support for thishypothesis comes from
other studies that show that amyloid positivity in nonde-
mented individuals is associated with memory impairment,
cognitive decline, increased amyloid deposition and brain at-
rophy rates, and mortality.45-48 Our study also indicates that
developmentofADpathologycanstart as early asage30years,
depending on the APOE genotype. Comparison with preva-
lence and lifetime risk estimates of AD-type dementia sug-
gests a 20- to 30-year interval between amyloid positivity and
dementia, implying that there is a large window of opportu-
nity to start preventive treatments. Still, the exact interval be-
tween theonsetof amyloidpositivity andonsetofAD-typede-
mentia needs to be assessed by long-term follow-up studies
because not all persons with amyloid pathology will become
dementedduring their lifetime,49 andnot all individualswith
a clinical diagnosis ofAD-typedementiahave amyloidpathol-
ogy. Because of the uncertainty about whether and when an
amyloid-positive individualwithoutdementiawilldevelopde-
mentia, amyloid positivity in these individuals should not be
equatedwith impending clinical dementia but rather be seen
as a risk state. Our prevalence rates can be used as an inex-
pensive andnoninvasive approach to select persons at risk for
amyloid positivity.
Conclusions
Amongpersonswithout dementia, the prevalence of cerebral
amyloidpathologyasdeterminedbyPET imagingorCSF find-
ings was associated with age, APOE genotype, and presence
of cognitive impairment. These findings suggest a 20- to 30-
year interval between first development of amyloid positiv-
ity and onset of dementia.
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